Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Michel, Tanja Maria | Gsell, Wieland | Käsbauer, Ludwig | Tatschner, Thomas | Sheldrick, Abigail Jane | Neuner, Irene | Schneider, Frank | Grünblatt, Edna | Riederer, Peter
Article Type: Research Article
Abstract: For decades, it has been acknowledged that oxidative stress due to free radical species contributes to the pathophysiology of aging and neurodegenerative diseases. Aldehyde dehydrogenases (ALDH) not only transform aldehydes to acids but also act as antioxidant enzymes. However, little is known about the implications of the enzymatic family of ALDH in the context of neurodegenerative processes such as Alzheimer's disease (AD). We therefore examined the enzymatic activity of the mitochondrial ALDH-isoform in different regions of the postmortem brain tissue isolated from patients with AD and controls. We found that the mitochondrial ALDH activity was significantly increased only in the …putamen of patients suffering from AD compared to controls. This is of particular interest since mediators of oxidative stress, such as iron, are increased in the putamen of patients with AD. This study adds to the body of evidence that suggests that oxidative stress as well as aldehyde toxicity play a role in AD. Show more
Keywords: Aging, aldehydehydrogenase, Alzheimer's disease, dementia, free radicals, mitochondria, oxidative stress
DOI: 10.3233/JAD-2010-1326
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1295-1301, 2010
Authors: del Valle, Jaume | Duran-Vilaregut, Joaquim | Manich, Gemma | Casadesús, Gemma | Smith, Mark A. | Camins, Antoni | Pallàs, Mercè | Pelegrí, Carme | Vilaplana, Jordi
Article Type: Research Article
Abstract: Late-onset Alzheimer's disease (AD) is the most common form of AD appearing after 65 years of age. To date, however, there are no non-genetically manipulated rodent models that develop a similar sporadic onset of AD with age-related amyloid-β (Aβ) deposition. Although the senescence accelerated mouse prone 8 (SAMP8) mice have been proposed as a model of AD, the presence of Aβ deposits remains controversial. In this study, we describe the time course of Aβ deposition in SAMP8 mice as well as in control SAMR1 and ICR-CD1 strains of mice. From as early as 6 months onward, SAMP8 mice show Aβ …deposition in the hippocampus that increase in number and extent with age. These deposits are comprised of by clustered granules that contain Aβ42 , Aβ40 , and other Aβ protein precursor fragments. By marked contrast, control mice show only low numbers of Aβ clusters that do not develop until 15 months of age. The demonstration that SAMP8 mice present with amyloid deposits in their hippocampus makes this animal model a useful tool to understand the mechanisms involved in Aβ deposition in AD. Show more
Keywords: Aβ40, Aβ42, AβPP, aging, Alzheimer's disease, amyloid-β, hippocampus, SAMP8, SAMR1, senescence
DOI: 10.3233/JAD-2010-1321
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1303-1315, 2010
Authors: Cantoni, Claudia | Fenoglio, Chiara | Cortini, Francesca | Venturelli, Eliana | Villa, Chiara | Clerici, Francesca | Marcone, Alessandra | Benussi, Luisa | Ghidoni, Roberta | Gallone, Salvatore | Scalabrini, Diego | Franceschi, Massimo | Cappa, Stefano | Binetti, Giuliano | Mariani, Claudio | Rainero, Innocenzo | Giordana, Maria Teresa | Bresolin, Nereo | Scarpini, Elio | Galimberti, Daniela
Article Type: Research Article
Abstract: Two hundred and fifty one Italian patients with sporadic frontotemporal lobar degeneration (FTLD) and 259 age-matched controls were tested for association with the tagging single nucleotide polymorphisms (SNPs) rs741810 and rs1052352 in the fused in sarcoma/translated in liposarcoma gene (FUS/TLS). Only patients negative for GRN mutations were included. Considering each SNP alone, no differences in either allelic or genotypic frequencies between patients and controls were found (P > 0.05), even stratifying according to gender or the presence of concomitant motor neuron disease. Haplotype analysis failed to detect haplotypes associated with FTLD. According to these results, FUS/TLS is not a susceptibility …factor for the development of sporadic FTLD. Show more
Keywords: Frontotemporal lobar degeneration (FTLD), fused in sarcoma/translated in liposarcoma (FUS/TLS), polymorphism, risk factor, variability
DOI: 10.3233/JAD-2010-1328
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1317-1322, 2010
Authors: Innocenti, Massimo | Salvietti, Emanuele | Guidotti, Martina | Casini, Angela | Bellandi, Silvano | Foresti, Maria Luisa | Gabbiani, Chiara | Pozzi, Andrea | Zatta, Paolo | Messori, Luigi
Article Type: Research Article
Abstract: Formation of amyloid-β (Aβ)1–42 amyloid fibrils, a characteristic feature of Alzheimer's disease (AD), was monitored in situ through atomic force microscopy (AFM). Well-structured amyloid fibrils slowly formed in solution within 24 hours for which high quality AFM pictures could be obtained. Remarkably, addition of either copper(II) or zinc(II) ions to the incubation medium, even at extremely low molar ratios, dramatically changed the Aβ1–42 aggregation profile and prevented fibril formation. Aggregates of different morphology appeared in accordance with previous observations: small globular aggregates upon addition of zinc; ill-structured micro-aggregates in the case of copper. The implications of these AFM …results are discussed in the context of current concepts for AD metallobiology. Show more
Keywords: Alzheimer's disease, amyloid-β, atomic force microscopy, metal ions
DOI: 10.3233/JAD-2010-1338
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1323-1329, 2010
Authors: Bowman, Gene L. | Shannon, Jackilen | Frei, Balz | Kaye, Jeffrey A. | Quinn, Joseph F.
Article Type: Research Article
Abstract: Oxidative damage is a consistent finding in a number of central nervous system (CNS) disorders. Uric acid (UA) is a potent hydrophilic antioxidant that is modified by diet and drug. Several lines of evidence suggest that plasma UA may modulate outcomes in neurologic disease, but little attention has been paid to CNS levels of UA. Our objective was to test the hypothesis that cerebrospinal fluid (CSF) UA is determined by plasma UA, modified by blood-brain barrier (BBB) integrity and associated with rate of cognitive decline in Alzheimer's disease (AD). Also, since UA and ascorbic acid may act as antioxidants for …one another, we also explored a potential interaction between them in the brain. Thirty-two patients with mild to moderate AD (Mini-Mental Status Exam 19 ± 5) participated in a longitudinal biomarker study for one year involving standardized clinical assessments. CSF and blood were collected at baseline for UA, ascorbic acid, and albumin. Cognitive measures were collected at baseline and again one year later. CSF UA was independent of age, gender, and AD severity. CSF and plasma UA were positively correlated (r = 0.669, p = 0.001) and BBB impairment was associated with higher CSF levels of UA (p = 0.028). Neither plasma nor CSF UA reached significant association with rates of cognitive decline over 1 year. CSF UA and CSF ascorbic acid were positively correlated (r = 0.388, p = 0.001). The hypothesis that CSF UA is determined by plasma UA and BBB integrity is supported, as is the hypothesis that UA and ascorbic acid are associated in CSF but not plasma. Adequately powered prospective studies would help assess any role for UA in primary and secondary prevention of AD. Show more
Keywords: Alzheimer's disease, ascorbic acid, blood-brain barrier, cerebrospinal fluid, uric acid
DOI: 10.3233/JAD-2010-1330
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1331-1336, 2010
Authors: Spitsin, Sergei | Koprowski, Hilary
Article Type: Article Commentary
DOI: 10.3233/JAD-2010-1336
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1337-1338, 2010
Authors: Doehner, Jana | Madhusudan, Amrita | Konietzko, Uwe | Fritschy, Jean-Marc | Knuesel, Irene
Article Type: Research Article
Abstract: Reelin is a large extracellular glycoprotein required for proper neuronal positioning during development. In the adult brain, Reelin plays a crucial modulatory role in the induction of synaptic plasticity and successful formation of long-term memory. Recently, alterations in Reelin-mediated signaling have been suggested to contribute to neuronal dysfunction associated with Alzheimer's disease (AD). We previously reported that aging in several species is characterized by a decline in Reelin-expressing interneurons and concomitant accumulation in amyloid-like plaques in the hippocampal formation, significantly correlating with cognitive impairments. In transgenic AD mice, we detected Reelin in oligomeric amyloid-β aggregates and in tight association with …fibrillary plaques. Here, we used immunohistochemistry at the light and electron microscopy level to characterize further the morphology, temporal and spatial progression, as well as the potential of Reelin-positive plaques to sequester murine amyloid-β peptides in wild-type mice. We developed a new immunohistochemical protocol involving a stringent protease pretreatment which markedly enhanced Reelin-immunoreactivity and allowed specific detection of variable shapes of murine anti-amyloid-β protein precursor-immunoreactivity in plaques in the hippocampus, likely representing N-terminal fragments and amyloid-β species. Ultrastructural investigations confirmed the presence of Reelin in extracellular space, somata of interneurons in young and aged wild-type mice. In aged mice, Reelin- and amyloid-β-immunoreactivity was detected in extracellular, spherical deposits, likely representing small intermediates or fragments of amyloid fibrils. Our results suggest that Reelin itself aggregates into abnormal oligomeric or protofibrillary deposits during aging, potentially creating a precursor condition for fibrillary amyloid-β plaque formation. Show more
Keywords: Amyloid-β plaques, AβPP, electron microscopy, hippocampus, immunohistochemistry, Mus musculus, non-transgenic, pepsin treatment, pre-fibrillary oligomers, sporadic Alzheimer's disease, stratum lacunosum-moleculare, ultrastructure
DOI: 10.3233/JAD-2010-1333
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1339-1357, 2010
Authors: Guo, Jian-Ping | Yu, Sheng | McGeer, Patrick L.
Article Type: Research Article
Abstract: Compounds that will inhibit buildup of amyloid-β(Aβ) deposits in Alzheimer's disease (AD) brain are potential therapeutic agents. Here we report the development of two simple in vitro screening assays to identify such agents. We use these assays to evaluate the relative potency of some possible candidates. One assay is based on binding of fluorescence-tagged Aβ1–42 to synthetic Aβ1–42 plated in wells of fluorescent black-wall microplates. Fluorescence-tagged Aβ1–42 solutions with and without blockers are then added to the plates, and the amount of bound fluorescence is measured. Another is a tissue type assay, where sections of unfixed AD …or AD model transgenic mouse brains are mounted on glass slides. The same solutions assayed in the microplate test are then added to tissue sections. Binding of fluorescence-tagged Aβ1–42 to the Aβ deposits in AD or transgenic brain tissue is detected with a fluorescence microscope. Good agreement is obtained between the two methods. Most of the tested agents have too low an affinity for Aβ1–42 to be effective clinically. Agents that may have marginal affinity according to these tests include 1,2,3,4,6-penta-O-galloyl-b-D-glucopyranose (PGG), S-diclofenac, epigallocatechin gallate (EGCG), resveratrol, and extracts of spirulina, ginger, rhubarb, cinnamon, blueberries, and turmeric. Compounds which failed to show binding include scyllo-inositol, myo-inositol, rhamnose, ginkgolide A, emodin, rhein, caryophellene, curcumin, valproic acid, tramiprosate, and garlic extract. Show more
Keywords: Blueberry, cinnamon, Congo red, epigallocatechin gallate, garlic, ginger, resveratrol, rhubarb, spirulina, S-diclofenac, senile plaques, turmeric
DOI: 10.3233/JAD-2010-1331
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1359-1370, 2010
Authors: Kim, Insub | Lee, Junhee | Hong, Hyun Joo | Jung, Eun Sun | Ku, Yun Hyi | Jeong, In Kyong | Cho, Young Min | So, Insuk | Park, Kyong Soo | Mook-Jung, Inhee
Article Type: Research Article
Abstract: Increasing evidence suggests that type 2 diabetes mellitus (T2DM) is strongly correlated with Alzheimer's disease (AD). To examine the relationship between T2DM and AD, autoantibodies against amyloid-Aβ were measured in the serum of T2DM patients and age-matched controls. Levels of Aβ autoantibody were measured by ELISA in serum samples of T2DM patients (n = 92) and age-matched control group (n = 106). Aβ autoantibody levels were increased in T2DM compared with age-matched controls by 45.4 ± 8.1% (p < 0.001). Females had higher Aβ autoantibody levels than males in both T2DM and control group. Aβ autoantibody levels in the T2DM …group were positively correlated with the levels of cholesterol (p = 0.011), low density lipoprotein cholesterol (p = 0.020), and triglycerides (p = 0.039). In conclusion, the level of Aβ autoantibody is dramatically elevated in patient serum of T2DM, and, as such, might be used as a possible biomarker for T2DM. Show more
Keywords: Aβ autoantibody, Alzheimer's disease, biomarker, cholesterol, type 2 diabetes mellitus
DOI: 10.3233/JAD-2010-1332
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1371-1376, 2010
Authors: Yenjerla, Mythili | LaPointe, Nichole E. | Lopus, Manu | Cox, Corey | Jordan, Mary Ann | Feinstein, Stuart C. | Wilson, Leslie
Article Type: Research Article
Abstract: NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) is a neuroprotective peptide that shows cognitive protection in patients with amnestic mild cognitive impairment, a precursor to Alzheimer's disease. NAP exhibits potent neuroprotective properties in several in vivo and cellular models of neural injury. While NAP has been found in many studies to affect microtubule assembly and/or stability in neuronal and glial cells at fM concentrations, it has remained unclear whether NAP acts directly or indirectly on tubulin or microtubules. We analyzed the effects of NAP (1 fM-1 μM) on the assembly of reconstituted bovine brain microtubules in vitro and found that it did not significantly (p …< 0.05) alter polymerization of either purified tubulin or of a mixture of tubulin and unfractionated microtubule-associated proteins. NAP also had no significant effect (p < 0.05) on the growing and shortening dynamics of steady-state microtubules at their plus ends, nor did it alter the polymerization or dynamics of microtubules assembled in the presence of 3-repeat or 4-repeat tau. Thus, the neuroprotective activity of NAP does not appear to involve a direct action on the polymerization or dynamics of purified tubulin or microtubules. Show more
Keywords: Microtubule dynamics, NAP, tau, tubulin polymerization
DOI: 10.3233/JAD-2010-1335
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1377-1386, 2010
Authors: Smith, Danielle G. | Ciccotosto, Giuseppe D. | Tew, Deborah J. | Perez, Keyla | Curtain, Cyril C. | Boas, John F. | Masters, Colin L. | Cappai, Roberto | Barnham, Kevin J.
Article Type: Research Article
Abstract: Amyloid-β peptide (Aβ) toxicity is thought to be responsible for the neurodegeneration associated with Alzheimer's disease. While the mechanism(s) that modulate this toxicity are still widely debated, it has previously been demonstrated that modifications to the three histidine residues (6, 13, and 14) of Aβ are able to modulate the toxicity. Therefore to further elucidate the potential role of the histidine (H) residues in Aβ toxicity, we synthesized Aβ peptides with single alanine substitutions for each of the three histidine residues and ascertained how these substitutions affect peptide aggregation, metal binding, redox chemistry, and cell membrane interactions, factors which have …previously been shown to modulate Aβ toxicity. Aβ42 H13A and Aβ42 H6A modified peptides were able to induce significant cell toxicity in primary cortical cell cultures at levels similar to the wild-type peptide. However, Aβ42 H14A did not induce any measurable toxicity in the same cultures. This lack of toxicity correlated with the inability of the Aβ42 H14A to bind to cell membranes. The interaction of Aβ with cell membranes has previously been shown to be dependent on electrostatic interactions between Aβ and the negatively charged head group of phosphatidylserine. Our data suggests that it is the imidazole sidechain of histidine 14 that modulates this interaction and strategies inhibiting this interaction may have therapeutic potential for Alzheimer's disease. Show more
Keywords: Amyloid, cell membrane, neurotoxicity, phosphatidylserine
DOI: 10.3233/JAD-2010-1334
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1387-1400, 2010
Authors: Koedam, Esther L.G.E. | Lauffer, Vivian | van der Vlies, Annelies E. | van der Flier, Wiesje M. | Scheltens, Philip | Pijnenburg, Yolande A.L.
Article Type: Research Article
Abstract: Alzheimer's disease (AD) is the most common cause of dementia at older age. Although less prevalent before the age of 65 years, it is still the most frequent cause of early-onset dementia followed by frontotemporal dementia. The typical presentation of AD is memory dysfunction, however, presentations with prominent cognitive impairment in other domains besides memory, like prominent apraxia, language problems, or executive dysfunction, may occur and are relatively more common in early-onset AD. In this retrospective descriptive study, we determined the prevalence of non-memory presentations in a large sample of early-onset AD patients compared to late-onset AD. The clinical files …of 270 patients with AD starting before the age of 65 years and 90 patients with late-onset AD (⩾ 65 years) were reviewed to assess clinical characteristics. Patients were classified as memory presentation and non-memory presentation according to their clinical presentation. The mean age of the early-onset group was 56 ± 5 years and 74 ± 6 years for the late-onset group. A third of the early-onset AD group presented with non-memory symptoms compared to only 6% in the late-onset group (p < 0.001). Within the group with non-memory presentations, apraxia/visuospatial dysfunction was the most prevalent presenting symptom (12%). Patients with early-onset AD often present with a non-memory phenotype, of which apraxia/visuospatial dysfunction is the most common presenting symptom. Atypical presentations of AD should be considered in the clinical differential diagnosis of early-onset dementia. Show more
Keywords: Alzheimer's disease, clinical presentation, dementia, early onset
DOI: 10.3233/JAD-2010-1337
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1401-1408, 2010
Authors: Dance, Amber | Landhuis, Esther | Strobel, Gabrielle
Article Type: Editorial
DOI: 10.3233/JAD-2010-1323
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1409-1415, 2010
Article Type: Announcement
DOI: 10.3233/JAD-2010-1327
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1417-1419, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl